Tarceva - Erlotinib - Genentech/Osi pharmaceuticals - Tyrosine kinase inhibitor approved for NSCLC

被引：0
|
作者：
不详
机构：
来源：
FORMULARY | 2004年 / 39卷 / 12期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：568 / 568
页数：1
相关论文
共 50 条
  • [31] Chemotherapy with erlotinib or chemotherapy alone in advanced NSCLC with acquired resistance to EGFR tyrosine kinase inhibitors (TKI)
    Goldberg, Sarah B.
    Oxnard, Geoffrey R.
    Digumarthy, Subba
    Muzikansky, Alona
    Jackman, David Michael
    Lennes, Inga Tolin
    Sequist, Lecia V.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [32] Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib
    Deeken, John F.
    Beumer, Jan H.
    Anders, Nicole M.
    Wanjiku, Teresia
    Rusnak, Milan
    Rudek, Michelle A.
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2015, 76 (04) : 813 - 819
  • [33] Preclinical assessment of the interactions between the antiretroviral drugs, ritonavir and efavirenz, and the tyrosine kinase inhibitor erlotinib
    John F. Deeken
    Jan H. Beumer
    Nicole M. Anders
    Teresia Wanjiku
    Milan Rusnak
    Michelle A. Rudek
    Cancer Chemotherapy and Pharmacology, 2015, 76 : 813 - 819
  • [34] Cancer combination therapy of the sesquiterpenoid artesunate and the selective EGFR-tyrosine kinase inhibitor erlotinib
    Efferth, Thomas
    PHYTOMEDICINE, 2017, 37 : 58 - 61
  • [35] An evaluation of the possible interaction of gastric acid suppressive medication and the EGFR tyrosine kinase inhibitor erlotinib
    Hilton, J. F.
    Seymour, L.
    Le Maitre, A.
    Tu, D.
    Shepherd, F. A.
    Bradbury, P. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [36] An evaluation of the possible interaction of gastric acid suppressing medication and the EGFR tyrosine kinase inhibitor erlotinib
    Hilton, J. F.
    Tu, D.
    Seymour, L.
    Shepherd, F. A.
    Bradbury, P. A.
    LUNG CANCER, 2013, 82 (01) : 136 - 142
  • [37] EGFR tyrosine kinase inhibitor erlotinib exhibits antimetastatic activity against inflammatory breast cancer
    Ueno, Naoto
    LaFortune, Tiffany
    Hortobagyi, Gabriel
    Lucci, Anthony
    Singh, Balraj
    Krishnamurthy, Savitri
    Esteva, Francisco
    Hung, Mien-Chie
    Zhang, Dongwei
    CANCER RESEARCH, 2009, 69
  • [38] Adverse events of sequential tyrosine kinase inhibitor following immune checkpoint inhibitor in advanced NSCLC patients
    Shimoda, Yukiko
    Miyakoshi, Jun
    Yoshida, Tatsuya
    Matsumoto, Yuji
    Masuda, Ken
    Shinno, Yuki
    Okuma, Yusuke
    Goto, Yasushi
    Horinouchi, Hidehito
    Yamamoto, Noboru
    Ohe, Yuichiro
    ANNALS OF ONCOLOGY, 2022, 33 : S482 - S483
  • [39] Efficacy of Tyrosine Kinase Inhibitor for Non-adenocarcinoma NSCLC Patients With EGFR Mutation
    Cho, S. H.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S620 - S620
  • [40] Patient Preferences for Tyrosine Kinase Inhibitor Treatments for EGFR Mutation Positive Metastatic NSCLC
    Bridges, J.
    De La Cruz, M.
    Pavilack, M.
    Flood, E.
    Janssen, E.
    Chehab, N.
    Fernandes, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S343 - S343
12345